BrightGene Bio-Medical Technology Future Growth
Future criteria checks 2/6
BrightGene Bio-Medical Technology is forecast to grow earnings and revenue by 18.2% and 14.4% per annum respectively. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be 9.8% in 3 years.
Key information
18.2%
Earnings growth rate
18.4%
EPS growth rate
| Pharmaceuticals earnings growth | 18.6% |
| Revenue growth rate | 14.4% |
| Future return on equity | 9.8% |
| Analyst coverage | Low |
| Last updated | 18 Sep 2024 |
Recent future growth updates
No updates
Recent updates
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 28% Price Boost Is Out Of Tune With Earnings
Oct 01
Is BrightGene Bio-Medical Technology (SHSE:688166) Using Too Much Debt?
Sep 19Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,777 | 312 | 303 | 585 | 3 |
| 12/31/2025 | 1,515 | 257 | 146 | 505 | 3 |
| 12/31/2024 | 1,325 | 217 | 36 | 404 | 3 |
| 6/30/2024 | 1,250 | 199 | -77 | 294 | N/A |
| 3/31/2024 | 1,215 | 196 | -48 | 318 | N/A |
| 12/31/2023 | 1,180 | 202 | -209 | 195 | N/A |
| 9/30/2023 | 1,160 | 234 | -185 | 204 | N/A |
| 6/30/2023 | 1,104 | 237 | -161 | 319 | N/A |
| 3/31/2023 | 1,074 | 250 | -176 | 366 | N/A |
| 12/31/2022 | 1,017 | 240 | -415 | 311 | N/A |
| 9/30/2022 | 1,076 | 265 | -533 | 299 | N/A |
| 6/30/2022 | 1,074 | 249 | -665 | 207 | N/A |
| 3/31/2022 | 1,112 | 256 | -821 | 143 | N/A |
| 12/31/2021 | 1,052 | 244 | -734 | 176 | N/A |
| 9/30/2021 | 1,023 | 225 | -765 | 149 | N/A |
| 6/30/2021 | 961 | 203 | -656 | 109 | N/A |
| 3/31/2021 | 844 | 184 | -439 | 164 | N/A |
| 12/31/2020 | 785 | 170 | -200 | 155 | N/A |
| 9/30/2020 | 700 | 169 | -50 | 144 | N/A |
| 6/30/2020 | 596 | 143 | -32 | 117 | N/A |
| 3/31/2020 | 544 | 129 | -38 | 70 | N/A |
| 12/31/2019 | 503 | 111 | -28 | 61 | N/A |
| 9/30/2019 | 466 | 96 | -20 | 41 | N/A |
| 6/30/2019 | 445 | 83 | -100 | 52 | N/A |
| 3/31/2019 | 410 | 74 | -91 | 43 | N/A |
| 12/31/2018 | 408 | 73 | -48 | 64 | N/A |
| 12/31/2017 | 317 | 46 | N/A | 36 | N/A |
| 12/31/2016 | 201 | 17 | N/A | 30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688166's forecast earnings growth (18.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 688166's earnings (18.2% per year) are forecast to grow slower than the CN market (23.3% per year).
High Growth Earnings: 688166's earnings are forecast to grow, but not significantly.
Revenue vs Market: 688166's revenue (14.4% per year) is forecast to grow faster than the CN market (13.2% per year).
High Growth Revenue: 688166's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688166's Return on Equity is forecast to be low in 3 years time (9.8%).